fbpx
Medical Innovation Exchange

Daiichi Sankyo’s survival data means it may finally be ready to compete with Novartis’, Astellas’ marketed AML meds

https://www.fiercebiotech.com/biotech/daiichi-sankyos-survival-data-means-it-may-finally-catch-novartis-astellas-aml-race

Leave a Comment

Your email address will not be published.

Leave the field below empty!

This site uses Akismet to reduce spam. Learn how your comment data is processed.